Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors | MicrobiomeTrials

← Back to trials

NCT06943755

Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors

RecruitingPHASE2, PHASE3INTERVENTIONAL

Trial Details

Start: 2025-07-21Est. Completion: 2029-06-30

Enrollment target: 440 participants

Locations

The University of Alabama at Birmingham, Birmingham, Alabama, United States
Mayo Clinic Hospital, Phoenix, Arizona, United States
The University of Arizona Cancer Center, Tucson, Arizona, United States
Cedars-Sinai Medical Center, Beverly Hills, California, United States
Norris Comprehensive Cancer Center, Los Angeles, California, United States
Stanford Cancer Center, Palo Alto, California, United States
UCLA Health - Santa Monica Cancer Care, Santa Monica, California, United States
Kaiser Permanente Medical Center, Vallejo, California, United States
Georgetown University, Washington D.C., District of Columbia, United States
Mayo Clinic - Florida, Jacksonville, Florida, United States
AdventHealth Orlando, Orlando, Florida, United States
Moffitt Cancer Center, Tampa, Florida, United States
University of Kentucky Markey Cancer Center, Lexington, Kentucky, United States
East Jefferson General Hospital, Metairie, Louisiana, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Other microbiome trials you might be interested in

Precision Radiotherapy Using MR-linac for Pancreatic Neuroendocrine Tumours in MEN1 PatientsRecruiting

Neuroendocrine Tumor of PancreasMultiple Endocrine Neoplasia Type 1

Patients with the Multiple Endocrine Neoplasia type 1 (MEN1) syndrome are genetically predisposed for developping multip…

Utrecht, NetherlandsEst. completion Jul 2027

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)Phase 2Recruiting

Pheochromocytoma/ParagangliomaPancreatic Neuroendocrine TumorVon Hippel-Lindau DiseaseAdvanced Gastrointestinal Stromal TumorHIF-2α Mutated Cancers

Apply or Learn More on ClinicalTrials.gov

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.